Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05799898
Recruiting Observational

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors

NCT05799898 · tracked via the Priya Life Science France tracker
Sponsor
Institut Mutualiste Montsouris
Phase
Observational
Started
2022-03-01
Last updated
2023-04-05

Condition(s) studied

CancerImmune Checkpoint InhibitorCardiovascular ComplicationImmune-related Adverse Event

Investigational drug(s) / intervention(s)

No intervention for research purposes only

No intervention for research purposes only: No intervention for research purposes only

Study summary

Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors.

Longitudinal prospective single center cohort. Inclusion criteria: all patient willing to particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors.

Description of patients characteristics, investigations, diagnosis after multidisciplinary meeting, outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors Exclusion Criteria: * none

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Intitut Mutualiste Montsouris Paris France Recruiting

More Institut Mutualiste Montsouris trials in France

Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty Recruiting
Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal Atrial Fibrillation (AF) Ablation Recruiting

Other trials for the same condition

Deployment of Teleconsulting in Geriatric Oncology for Older Patients Recruiting
Vulnerability and Risk of Neuropathic Pain in Cancer Recruiting
Description of the Stroma of Solid Tumors (DISTRO) Active, not recruiting
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
Impact of a Collaborative Program of Physical Activity of Newly-diagnosed Cancer Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05799898 on ClinicalTrials.gov ↗ ← All trials in France